Company intelligence / Profile preview

K-PAX Pharmaceuticals, Inc.

Mill Valley, California, United Stateskpaxhealth.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Clinical trials showed KPAX002 (methylphenidate plus K-PAX Immune) improved overall Chronic Fatigue Syndrome symptoms by 34% at 12 weeks and reduced Gulf War Illness symptoms by 25% at 12 weeks. The micronutrient formula also improved CD4 cell count in HIV-infected patients taking HAART[10].

Therapeutic areas: OtherImmunologyInfectious Diseases
Modalities: Micronutrient formulasCombination therapies (supplements with pharmaceuticals)
Industry: Biotech

Drug pipeline

4 assets

Core Energy

Commercial

Indications: Fatigue, Mitochondrial dysfunction

3 more assets in the full pipeline.

Request access →

Partnerships

Previously partnered with Bristol-Myers Squibb for research funding[5]

Beyond the preview

Go deeper on K-PAX Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K-PAX Pharmaceuticals, Inc..

Explore the full profile